Lakeview Clinical Research

Help us learn more about RSV vaccination

Those who qualify may receive:

  • Study-related care from local doctors at no cost
  • Reimbursement for study-related travel
  • Study vaccines at no cost

There is no obligation, so see if you may qualify now.


RSV infects the lungs, nose, throat and breathing passages, and causes common cold-like symptoms. Both RSV infection and pneumococcal disease peak during the winter season.

RSV can infect people of all ages including older adults, who may develop serious complications leading to hospitalization.

What to expect
The investigational vaccine will be studied alongside an approved 20-valent pneumococcal conjugate vaccine (PCV20). Pneumococcal infections can cause problems such as pneumonia and meningitis. Like RSV, pneumonia can severely affect older adults.

If you choose to take part in the study, you will be randomly assigned to either Group 1 or Group 2.

  • If you are in Group 1, you will receive PCV20 and the investigational vaccine on the same day. You will be in the study for 6 months. You will have 2 study center visits and 1 phone call.
  • If you are in Group 2, you will receive PCV20 first (Day 1) and the investigational vaccine 30 days later (Day 31). You will be in the study for 7 months. You will have 3 study center visits and 1 phone call.


Our team will contact you to verify your eligiblity and answer any questions you may have.